Chenjing Xia
Impact in
- Oncology top 10%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
Papers in
-
- Advanced biosensing and bioanalysis techniques 3
- RNA Interference and Gene Delivery 2
- Epigenetics and DNA Methylation 1
- Melanoma and MAPK Pathways 1
- PI3K/AKT/mTOR signaling in cancer 1
-
- MicroRNA in disease regulation 3
- Co-authors
- Tim Eisen (1 shared paper)Melanie Poulin-Costello (1 shared paper)Peter J. O’Dwyer (1 shared paper)Brian Schwartz (1 shared paper)Ronit Simantov (1 shared paper)Martin Gore (1 shared paper)Lynn M. Schuchter (1 shared paper)I. Gibbens (1 shared paper)
- Journals
- British Journal of Cancer (2 papers)Frontiers in Pharmacology (1 paper)Sensors and Actuators B Chemical (1 paper)Talanta (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Chenjing Xia
8 papers receiving 558 citations
Chenjing Xia's Hit Papers
Peers
Comparison fields: 5 of 47
- Oncology 282
- Molecular Biology 431
- Pathology and Forensic Medicine 66
- Computational Theory and Mathematics 67
- Cancer Research 41
Countries citing papers authored by Chenjing Xia
This map shows the geographic impact of Chenjing Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenjing Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenjing Xia more than expected).
Fields of papers citing papers by Chenjing Xia
This network shows the impact of papers produced by Chenjing Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenjing Xia. The network helps show where Chenjing Xia may publish in the future.
Co-authors
The 25 scholars most cited alongside Chenjing Xia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Hit paper breakdown → | 2006 | 520 |
| 2 | 2018 | 34 | |
| 3 | 2011 | 10 | |
| 4 | 2023 | 8 | |
| 5 | 2009 | 3 | |
| 6 | 2025 | 2 | |
| 7 | 2025 | 1 | |
| 8 | 2025 | 1 | |
| 9 | 2025 | 0 |
About Chenjing Xia
Chenjing Xia is a scholar working on Molecular Biology, Cancer Research, Oncology, Pharmacology and Infectious Diseases, having authored 9 papers that have together received 579 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (3 papers), Advanced biosensing and bioanalysis techniques (3 papers), RNA Interference and Gene Delivery (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Epigenetics and DNA Methylation (1 paper), Cutaneous Melanoma Detection and Management (1 paper), Melanoma and MAPK Pathways (1 paper) and PI3K/AKT/mTOR signaling in cancer (1 paper). The work is most often cited by research in Oncology (282 citations), Molecular Biology (431 citations), Pathology and Forensic Medicine (66 citations), Computational Theory and Mathematics (67 citations) and Cancer Research (41 citations). Chenjing Xia has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Tim Eisen, Melanie Poulin-Costello, Peter J. O’Dwyer, Brian Schwartz, Ronit Simantov, Martin Gore, Lynn M. Schuchter, I. Gibbens, Keith T. Flaherty and Maggie James. Their work appears in journals such as British Journal of Cancer, Frontiers in Pharmacology, Sensors and Actuators B Chemical, Talanta and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.